We are live on ! Find out more
PLXP

PLx Pharma Inc. Common Stock
PLXP

Delisted

PLXP was delisted on the 12th of April, 2023.

Back to rankings

15 hedge funds and large institutions have $17M invested in PLx Pharma Inc. Common Stock in 2014 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 4

15% more funds holding

Funds holding: 13 → 15 (+2)

18% less capital invested

Capital invested by funds: $20.7M → $17M (-$3.65M)

40% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 5

Holders
15
Holders Change
+2
Holders Change %
+15.38%
% of All Funds
0.43%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
3
Reduced
5
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
KCM
Kingdon Capital Management
New York
+$243K
2
BC
Broadfin Capital
New York
+$148K
3
OC
Oppenheimer & Co
New York
+$132K
4
Deutsche Bank
Deutsche Bank
Germany
+$15.3K
5
BIM
BlackRock Investment Management
Delaware
+$5.29K

Top Sellers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
-$1.22M
2
HCMT
Highland Capital Management (Texas)
Texas
-$1.06M
3
Morgan Stanley
Morgan Stanley
New York
-$308K
4
SFM
Sphera Funds Management
Israel
-$297K
5
Millennium Management
Millennium Management
New York
-$252K
Name Holding Trade Value Shares
Change 		Change in
Stake
KCM
1
Kingdon Capital Management
New York
$6.82M +$243K +3,125 +4%
BC
2
Broadfin Capital
New York
$4.61M +$148K +1,900 +3%
PRCM
3
Pine River Capital Management
Minnesota
$2M – – –
TCM
4
Timpani Capital Management
Wisconsin
$1.32M -$139K -1,782 -10%
GPP
5
Great Point Partners
Connecticut
$1.2M -$1.22M -15,734 -50%
SFM
6
Sphera Funds Management
Israel
$916K -$297K -3,825 -24%
OC
7
Oppenheimer & Co
New York
$132K +$132K +1,698 New
TRCT
8
Tower Research Capital (TRC)
New York
$17K -$5.52K -71 -24%
Deutsche Bank
9
Deutsche Bank
Germany
$15K +$15.3K +197 New
GSC
10
Ground Swell Capital
South Carolina
$6K +$5.91K +76 New
Wells Fargo
11
Wells Fargo
California
$5K +$1.94K +25 +66%
U
12
UBS
Switzerland
$5K +$4.9K +63 New
BIM
13
BlackRock Investment Management
Delaware
$5K +$5.29K +68 New
Morgan Stanley
14
Morgan Stanley
New York
$2K -$308K -3,958 -99%
FANJ
15
Financial Architects (New Jersey)
New Jersey
$1K +$1.48K +19 New
HCMT
16
Highland Capital Management (Texas)
Texas
– -$1.06M -13,255 Closed
Millennium Management
17
Millennium Management
New York
– -$252K -3,125 Closed
PG
18
PEAK6 Group
Illinois
– -$148K -1,838 Closed
SIP
19
Stoneridge Investment Partners
Pennsylvania
– -$101K -1,250 Closed

PLXP Hedge Fund Activity: Q2 2014 in Review

15 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in PLx Pharma Inc. Common Stock (PLXP) for Q2 2014, worth a combined $17M — down 18% from $20.7M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new PLXP positions and 4 closed out — a net gain of 2 holders — while 3 added to existing stakes and 5 trimmed.

The largest buyer was Kingdon Capital Management, adding an estimated $243K. The largest seller was Great Point Partners, cutting an estimated $1.22M.

  • 15 institutional investors held PLx Pharma Inc. Common Stock (PLXP) as of Q2 2014, up from 13 in Q1 2014.
  • Funds reported $17M of PLx Pharma Inc. Common Stock stock for Q2 2014, down 18% quarter-over-quarter.
  • 6 funds opened new PLx Pharma Inc. Common Stock positions in Q2 2014 and 4 closed out, a net change of +2 holders.
  • The largest PLx Pharma Inc. Common Stock buyer in Q2 2014 was Kingdon Capital Management, an estimated $243K added.
  • The largest PLx Pharma Inc. Common Stock seller in Q2 2014 was Great Point Partners, an estimated $1.22M sold.

Based on aggregated 13F filings for Q2 2014.